Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shen Lu

Showing results (161-170 of 237) with videos related to

Pageof 24
Sort By:
Therapeutic Advances in Medical Oncology|August 13, 2020
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)Nadia Harbeck, Fabio Franke, Rafael Villanueva-Vazquez, et al.
BMC Cancer|July 15, 2016
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancerBang-Bin Chen, Yen-Shen Lu, Ching-Hung Lin, et al.
Cell Reports. Medicine|December 27, 2024
Hormone therapy enhances anti-PD1 efficacy in premenopausal estrogen receptor-positive and HER2-negative advanced breast cancerI-Chun Chen, Ching-Hung Lin, Dwan-Ying Chang, et al.
Cancer Medicine|July 24, 2024
Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysisMing-Han Yang, Chiun-Sheng Huang, Dwan-Ying Chang, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 14, 2022
Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian WomenChing-Hung Lin, Muhammad Zahid, Wen-Hung Kuo, et al.
The Oncologist|August 3, 2019
Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western PopulationsChing-Hsuan Chen, Yen-Shen Lu, Ann-Lii Cheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 26, 2003
Superoxo, mu-peroxo, and mu-oxo complexes from heme/O2 and heme-Cu/O2 reactivity: copper ligand influences in cytochrome c oxidase modelsEunsuk Kim, Matthew E Helton, Ian M Wasser, et al.
Breast Cancer Research : BCR|June 12, 2024
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatmentHuang-Chun Lien, Chiao Lo, Yi-Hsuang Lee, et al.
Journal of Clinical Pathology|June 7, 2011
Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?Ching-Hung Lin, Yen-Shen Lu, Chiun-Sheng Huang, et al.
Breast Cancer Research : BCR|September 10, 2024
Characteristics and transcriptional regulators of spontaneous epithelial-mesenchymal transition in genetically unperturbed patient-derived non-spindled breast carcinomaHuang-Chun Lien, Hui-Chieh Yu, Wen-Hsuan Yu, et al.
Pageof 24

Showing results (161-170 of 237) with videos related to

Sort By:
Pageof 24
Therapeutic Advances in Medical Oncology|August 13, 2020
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)Nadia Harbeck, Fabio Franke, Rafael Villanueva-Vazquez, et al.
BMC Cancer|July 15, 2016
A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancerBang-Bin Chen, Yen-Shen Lu, Ching-Hung Lin, et al.
Cell Reports. Medicine|December 27, 2024
Hormone therapy enhances anti-PD1 efficacy in premenopausal estrogen receptor-positive and HER2-negative advanced breast cancerI-Chun Chen, Ching-Hung Lin, Dwan-Ying Chang, et al.
Cancer Medicine|July 24, 2024
Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysisMing-Han Yang, Chiun-Sheng Huang, Dwan-Ying Chang, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 14, 2022
Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian WomenChing-Hung Lin, Muhammad Zahid, Wen-Hung Kuo, et al.
The Oncologist|August 3, 2019
Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western PopulationsChing-Hsuan Chen, Yen-Shen Lu, Ann-Lii Cheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 26, 2003
Superoxo, mu-peroxo, and mu-oxo complexes from heme/O2 and heme-Cu/O2 reactivity: copper ligand influences in cytochrome c oxidase modelsEunsuk Kim, Matthew E Helton, Ian M Wasser, et al.
Breast Cancer Research : BCR|June 12, 2024
In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatmentHuang-Chun Lien, Chiao Lo, Yi-Hsuang Lee, et al.
Journal of Clinical Pathology|June 7, 2011
Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?Ching-Hung Lin, Yen-Shen Lu, Chiun-Sheng Huang, et al.
Breast Cancer Research : BCR|September 10, 2024
Characteristics and transcriptional regulators of spontaneous epithelial-mesenchymal transition in genetically unperturbed patient-derived non-spindled breast carcinomaHuang-Chun Lien, Hui-Chieh Yu, Wen-Hsuan Yu, et al.
Pageof 24